Top 1% Biotech Crashes On A Shock For Its Top Drug
The company deprioritized its leading asset after the drug missed its mark in a proof-of-concept study.

Source: Investor's Business Daily
The company deprioritized its leading asset after the drug missed its mark in a proof-of-concept study.